Navigation Links
Wilson Therapeutics Announces Successful Filing of U.S. IND to Advance WTX101 Development Program for Wilson Disease
Date:1/13/2014

STOCKHOLM, Jan. 13, 2014 /PRNewswire/ -- Wilson Therapeutics, a privately-held biopharmaceutical company, today announced that it has successfully filed an Investigational New Drug (IND) application with U.S. Food and Drug Administration for the development of WTX101 (bis-choline tetrathiomolybdate), a novel de-coppering agent under evaluation as a treatment for Wilson Disease. The recent acceptance of the U.S. IND is a key initial step in the company's plan to advance WTX101 into pivotal clinical trials as a treatment for Wilson Disease, a rare genetic disorder that prevents the body from regulating copper and can lead to serious liver and brain damages.

"This IND enables us to proceed with a Phase 1 study that will provide additional pharmacokinetic and bioavailability data to support the overall development of WTX101 as it moves towards late stage, pivotal trials," said David Clark, M.D., chief medical officer of Wilson Therapeutics. "We expect to conduct this study quickly as we advance the WTX101 program forward this year."

WTX101 is the proprietary bis-choline formulation of tetrathiomolybdate (TTM), which has been evaluated in clinical studies in over 500 patients in various indications. TTM has been shown to rapidly lower copper levels. Previous data also suggest that TTM may stabilize neurological function and reduce the risk of neurological deterioration after initiation of treatment in Wilson Disease patients with neurological disease. WTX101 has also been tested in oncologic clinical trials and was shown to be safe and tolerable while efficiently lowering copper levels with once-daily dosing. WTX101 has received orphan drug designation in both the United States and the European Union.

"There remains a serious unmet need in the treatment of Wilson Disease patients, particularly those who present wit
'/>"/>

SOURCE Wilson Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Wilson Sonsini Goodrich & Rosati Elects Four New Partners
2. Charlie Wilson Teams Up With Janssen Biotech to Launch Making Awareness a Priority (M.A.P.)
3. TrialNetworks Customer Steve Sweeney of Arteaus Therapeutics Encourages Clinical Trial Sponsors to Treat Investigative Sites Like Customers by Using Innovative Technology
4. Halozyme Therapeutics To Present At The 32nd Annual J.P. Morgan Healthcare Conference
5. Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors
6. Spark Therapeutics Expands Leadership Team to Support Development and Commercialization of its Late-Stage Gene Therapy Pipeline
7. Adheron Therapeutics Announces Favorable Phase 1 Clinical Trial Results
8. Todd Rider Joins Draper to Continue Antiviral Therapeutics Development
9. Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
10. Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference
11. Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)...  Susan Hedstrom, Executive Director of the Foundation ... to supporting research to advance the understanding and ... FPWR has received the organization,s largest donation to ... $1 million in support of the organization,s research ... "Our gift signifies our tremendous trust ...
(Date:5/21/2015)... 2015  The EveryLife Foundation for Rare Diseases ... Amy Klobuchar (D-MN) today for introducing ... Treatments, or OPEN ACT. Supported by ... this bipartisan legislation promises to rapidly bring hundreds ... disease patients by incentivizing drug makers to "repurpose" ...
(Date:5/21/2015)... 21, 2015 Patent Offering, The patent’s ... diagnostic or therapeutic imaging within a body lumen (open ... endoscope having a low cost, single-use disposable illumination and ... was October 18, 2013 and the patent approval was ... the physician to customize the lighting and magnification of ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
Breaking Biology Technology:The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Global Survey on Flow Cytometry Adoption Trends 2015 2
... Jan. 2 Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ... JPMorgan Healthcare Conference on Monday, January 7, at ... live webcast of the,presentation at:, http://www.metameetings.com/webcasts/jpmorgan/healthcare08 ... on 15 minutes early in order to,register and ...
... CALGARY, Jan. 3 /PRNewswire-FirstCall/ - Oncolytics Biotech ... U.S.,National Cancer Institute (NCI) has filed a ... (FDA) for a Phase 1/2 clinical trial ... tube cancers using concurrent,systemic and intraperitoneal administration ...
... GATOS, Calif., Dec. 31 Three Palm ... that it has received 510(k) clearance,from the ... its WorkstationOne(TM),Breast Imaging Workstation. WorkstationOne is intended ... images, and was developed with,the goal of ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R) 2
(Date:5/22/2015)... CT , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... June 1st, it will be ending its promotional pricing and ... . Laurence Savin , Head of Marketing ... exclusive promotional pricing until the end of May. To get ... wocketwallet.com/invite and when we open the store on June 1, ...
(Date:5/21/2015)... 21, 2015 The Sync Project™ , ... for health, today announced a collaborative partnership with ... will center on collaboration on original research, joint course ... in the collaboration, The Sync Project and BerkleeICE are ... Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... pharmaceuticals can both prevent and treat Alzheimer,s Disease in mice. ... used for certain types of neuroimaging. "We looked at ... pathology was at an early stage, and in aged mice ... of the USC Davis School of Gerontology. "TSPO ligand reduced ...
... phosphatidylserine is a natural food supplement produced from beef, ... memory loss, it,s a popular treatment for older people ... Gil Ast and Dr. Ron Bochner of Tel Aviv ... discovered that the same supplement improves the functioning of ...
... past few decades, scientists have developed many devices that ... stents. While generally effective, each of these treatments has ... new study from MIT analyzes the potential usefulness of ... balloons and drug-releasing stents, but may pose fewer risks. ...
Cached Biology News:Drugs found to both prevent and treat Alzheimer's disease in mice 2Common food supplement fights degenerative brain disorders 2Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3
... MBS Start up kit. Includes configured Laptop ... of 2 MultiBlock satellite thermal cyclers ... User friendly software. Store/track run ... heated lid. Outstanding uniformity. Advanced ...
... The Lambda 10-2 is a microprocessor ... impressive speed coupled with exceptionally smooth ... for research applications involving fluorescence microscopy, ... any application requiring rapid and accurate ...
PTFE/red rubber septum silver aluminum seal ,11 mm seal diam. ...
... α-Amylase is a hydrolytic enzyme ... a mixture of glucose, maltose, maltotriose ... various fluids of the human,body are ... microbial,a-amylases are important enzymes for industry.4, ...
Biology Products: